New Zealand markets open in 7 hours 50 minutes

Palatin Technologies, Inc. (PTN)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
1.6700+0.0200 (+1.23%)
As of 10:03AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.6500
Open1.6400
Bid1.6400 x 900
Ask1.6700 x 900
Day's range1.6700 - 1.6700
52-week range1.4300 - 5.6500
Volume865
Avg. volume130,159
Market cap26.948M
Beta (5Y monthly)1.01
PE ratio (TTM)N/A
EPS (TTM)-2.7200
Earnings date26 Sept 2024 - 30 Sept 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.67
  • PR Newswire

    Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

    Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the Company issued in November 2022 and October 2023 totaling 3,233,277 shares of the Company's common stock for gross proceed

  • PR Newswire

    Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced the initiation of a Phase 2 clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy. Topline data from the Phase 2

  • PR Newswire

    Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

    Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate the safety and efficacy of bremelanotide, a melanocortin 4 receptor (MC4R) agonist, co-administered with tirzepatide (GLP-1/GIP) in obese patients. The primary endpo